

ABSTRACT

The present invention, which is applicable in the pharmaceutical industry, relates to the use of molsidomine or one of its pharmaceutically acceptable salts, especially in the form of a sustained-release solid oral composition effective over 24 hours, for the manufacture of a drug for preventing or reducing the development of atherosclerosis.